Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial

摘要: 504 evaluable node positive oestrogen receptor (ER) breast cancer patients were randomly allocated to receive either 5 years tamoxifen treatment or chemotherapy [six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 4 epirubicin] a combination both treatments. At median follow-up appeared be more effective than chemotherapy, the difference being highly significant in postmenopausal women. The addition was not able significantly improve results achieved alone, irrespective menopausal status. Trends similar even after stratification for number involved nodes. protective effect terms reduction odds death increased with time no rebound phenomena on recurrence has occurred so far completion treatment. Overall, prognostic value nodes progesterone (PgR) status confirmed multivariate analysis. However, predictive PgR lost receiving alone. Similarly, degree ER positivity response tamoxifen. Tamoxifen should still regarded as gold standard patients. In younger women antioestrogen proved safe at least chemotherapy. analysis annual risks suggests that concurrent sequential use might represent appropriate this patient subset, particularly those four Different cut-offs assays from we have arbitrarily employed present probably used select properly who can benefit endocrine therapy.